Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics is developing DCVax® personalized dendritic cell-based therapeutic vaccines for solid tumor cancers.The Company’s lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma, the most aggressive & lethal form of brain cancer.This Phase III trial is completed & the trial data are being analyzed.The Company’s second product, DCVax®-Direct, has completed a 40-patient Phase I trial for direct injection into all types of inoperable solid tumor cancers.The Company has conducted Phase I/II trials for late stage ovarian cancer & prostate cancer.